Company / Operating Cash Flow per Share
Trevi Therapeutics, Inc. Operating Cash Flow per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.38
FY2024
5-year range
-$1.61 / -$0.32
FY2020-FY2024
Trend
-17.2%
vs FY2023
Sector context
#92 of 212
Health Care
What the data says
At $-0.38, Trevi Therapeutics, Inc.'s operating cash flow per share ranks #92 of 212 in the Health Care sector. Improved from $-0.44 to $-0.38 over the past 2 years.
Based on SEC 10-K filings.
-0.38 in FY2024.
Improved from $-0.44 to $-0.38 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#92 of 212 in Health CareTop 43% of 212This company -$0.38 Sector average -$14.72
▼
+97.5% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share decreased 17.2% year-over-year.
- Ranks #92 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2023.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.38 | -17.2% |
| FY2023 | -$0.32 | +26.7% |
| FY2022 | -$0.44 | +65.6% |
| FY2021 | -$1.27 | +21.1% |
| FY2020 | -$1.61 | +18.4% |
| FY2019 | -$1.97 | +95.3% |
| FY2018 | -$41.79 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026